504 related articles for article (PubMed ID: 19691554)
1. The development of the RTS,S malaria vaccine candidate: challenges and lessons.
Ballou WR
Parasite Immunol; 2009 Sep; 31(9):492-500. PubMed ID: 19691554
[TBL] [Abstract][Full Text] [Related]
2. [The malaria vaccine candidate RTS,S/AS is in phase III clinical trials].
Cohen J; Benns S; Vekemans J; Leach A
Ann Pharm Fr; 2010 Nov; 68(6):370-9. PubMed ID: 21073995
[TBL] [Abstract][Full Text] [Related]
3. The RTS,S malaria vaccine.
Casares S; Brumeanu TD; Richie TL
Vaccine; 2010 Jul; 28(31):4880-94. PubMed ID: 20553771
[TBL] [Abstract][Full Text] [Related]
4. Development of the RTS,S/AS malaria candidate vaccine.
Vekemans J; Leach A; Cohen J
Vaccine; 2009 Dec; 27 Suppl 6():G67-71. PubMed ID: 20006143
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya.
Stoute JA; Heppner DG; Mason CJ; Siangla J; Opollo MO; Kester KE; Vigneron L; Voss G; Walter MJ; Tornieporth N; Cohen JD; Ballou WR
Am J Trop Med Hyg; 2006 Jul; 75(1):166-70. PubMed ID: 16837726
[TBL] [Abstract][Full Text] [Related]
6. RTS,S/AS02A for malaria.
Bojang KA
Expert Rev Vaccines; 2006 Oct; 5(5):611-5. PubMed ID: 17181435
[TBL] [Abstract][Full Text] [Related]
7. Malaria vaccine gets shot in the arm from tests.
Maher B
Nature; 2008 Dec; 456(7223):680-1. PubMed ID: 19079013
[No Abstract] [Full Text] [Related]
8. Vaccine development against malaria.
Matuschewski K
Curr Opin Immunol; 2006 Aug; 18(4):449-57. PubMed ID: 16765576
[TBL] [Abstract][Full Text] [Related]
9. Methods for determining vaccine efficacy and effectiveness and the main barriers to developing a fully deployable malaria vaccine.
Guinovart C; Alonso PL
Am J Trop Med Hyg; 2007 Dec; 77(6 Suppl):276-81. PubMed ID: 18165503
[TBL] [Abstract][Full Text] [Related]
10. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.
Kester KE; Cummings JF; Ockenhouse CF; Nielsen R; Hall BT; Gordon DM; Schwenk RJ; Krzych U; Holland CA; Richmond G; Dowler MG; Williams J; Wirtz RA; Tornieporth N; Vigneron L; Delchambre M; Demoitie MA; Ballou WR; Cohen J; Heppner DG;
Vaccine; 2008 Apr; 26(18):2191-202. PubMed ID: 18387719
[TBL] [Abstract][Full Text] [Related]
11. Progress towards the development of malaria vaccines.
Malkin E; Dubovsky F; Moree M
Trends Parasitol; 2006 Jul; 22(7):292-5. PubMed ID: 16707275
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique.
Macete E; Aponte JJ; Guinovart C; Sacarlal J; Ofori-Anyinam O; Mandomando I; Espasa M; Bevilacqua C; Leach A; Dubois MC; Heppner DG; Tello L; Milman J; Cohen J; Dubovsky F; Tornieporth N; Thompson R; Alonso PL
Trop Med Int Health; 2007 Jan; 12(1):37-46. PubMed ID: 17207146
[TBL] [Abstract][Full Text] [Related]
13. The RTS,S vaccine candidate for malaria.
Regules JA; Cummings JF; Ockenhouse CF
Expert Rev Vaccines; 2011 May; 10(5):589-99. PubMed ID: 21604980
[TBL] [Abstract][Full Text] [Related]
14. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial.
Sacarlal J; Aponte JJ; Aide P; Mandomando I; Bassat Q; Guinovart C; Leach A; Milman J; Macete E; Espasa M; Ofori-Anyinam O; Thonnard J; Corachan S; Dubois MC; Lievens M; Dubovsky F; Ballou WR; Cohen J; Alonso PL
Vaccine; 2008 Jan; 26(2):174-84. PubMed ID: 18069097
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys.
Walsh DS; Pichyangkul S; Gettayacamin M; Tongtawe P; Siegrist CA; Hansukjariya P; Kester KE; Holland CA; Voss G; Cohen J; Stewart AV; Miller RS; Ballou WR; Heppner DG
Am J Trop Med Hyg; 2004 May; 70(5):499-509. PubMed ID: 15155981
[TBL] [Abstract][Full Text] [Related]
16. Challenges in malaria control in sub-Saharan Africa: the vaccine perspective.
Lusingu JP; Von Seidlein L
Tanzan J Health Res; 2008 Oct; 10(4):253-66. PubMed ID: 19402588
[TBL] [Abstract][Full Text] [Related]
17. Malaria vaccines: are we getting closer?
Epstein JE; Giersing B; Mullen G; Moorthy V; Richie TL
Curr Opin Mol Ther; 2007 Feb; 9(1):12-24. PubMed ID: 17330398
[TBL] [Abstract][Full Text] [Related]
18. From the circumsporozoite protein to the RTS, S/AS candidate vaccine.
Cohen J; Nussenzweig V; Nussenzweig R; Vekemans J; Leach A
Hum Vaccin; 2010 Jan; 6(1):90-6. PubMed ID: 19806009
[TBL] [Abstract][Full Text] [Related]
19. Mosquirix (RTS,S): a novel vaccine for the prevention of Plasmodium falciparum malaria.
Wilby KJ; Lau TT; Gilchrist SE; Ensom MH
Ann Pharmacother; 2012 Mar; 46(3):384-93. PubMed ID: 22408046
[TBL] [Abstract][Full Text] [Related]
20. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
Stewart VA; McGrath SM; Walsh DS; Davis S; Hess AS; Ware LA; Kester KE; Cummings JF; Burge JR; Voss G; Delchambre M; Garçon N; Tang DB; Cohen JD; Heppner DG
Vaccine; 2006 Oct; 24(42-43):6483-92. PubMed ID: 16904798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
